Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Short Interest Update

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 1,343,395 shares, an increase of 161.1% from the May 31st total of 514,441 shares. Approximately 2.8% of the company’s shares are short sold. Based on an average trading volume of 282,980 shares, the short-interest ratio is presently 4.7 days.

Odyssey Therapeutics Price Performance

ODTX opened at $18.06 on Monday. Odyssey Therapeutics has a 1 year low of $15.35 and a 1 year high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 EPS for the quarter, topping analysts’ consensus estimates of ($1.31) by $1,000.31.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ODTX. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Wedbush started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target on the stock. Zacks Research raised Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Cantor Fitzgerald started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating on the stock. Finally, Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Odyssey Therapeutics has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Buying and Selling at Odyssey Therapeutics

In other news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $18.00, for a total transaction of $32,040.00. Following the sale, the insider owned 440,981 shares in the company, valued at $7,937,658. The trade was a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nan (Ln) Li acquired 1,111,111 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the purchase, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. This trade represents a 50.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 4,183,777 shares of company stock valued at $75,319,986 over the last three months.